FDA Approves Lipfendra (enlicitide), the First Oral PCSK9 Inhibitor for LDL-C Reduction

Aug 28

5 min read

Hypercholesterolemia occurs when blood levels of low-density lipoprotein cholesterol (LDL-C) are elevated (1). High LDL-C is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), which remains a leading cause of mortality worldwide and in the United States (1,2). Excess circulating LDL-C progressively deposits within arterial walls, accelerating plaque formation, narrowing vessels, and restricting blood flow. Plaque rupture can precipitate thrombosis, markedly increasing the risk of myocardial infarction or stroke. Because hypercholesterolemia is typically asymptomatic, many individuals remain undiagnosed until routine lipid testing (1). Contributing factors include poor diet, physical inactivity, excess body weight, and genetic conditions such as heterozygous familial hypercholesterolemia (HeFH), which is diagnosed using clinical criteria or genetic testing (1,2).

Unmet Needs in Lipid Management

Pharmacological strategies for lowering LDL-C include statins, ezetimibe, and injectable PCSK9 inhibitors (1). Yet, even with maximally tolerated statin therapy, many high-risk patients fail to reach target LDL-C levels (1,2). While injectable PCSK9 inhibitors deliver potent LDL-C reduction, their subcutaneous administration can limit patient adherence (1,2).

Michael Davis, M.D., PhD, Acting Director of the FDA’s Center for Drug Evaluation and Research, highlighted that the advent of an oral PCSK9 inhibitor broadens therapeutic options and advances the management of chronic cardiovascular disease (1). Katherine Wilemon, CEO of the Family Heart Foundation, underscored that timely LDL-C management represents a critical opportunity to reduce ASCVD risk (2).

FDA approval of the First Oral PCSK9 Inhibitor for LDL-C Reduction

On July 17, 2026, the U.S. Food and Drug Administration (FDA) approved Lipfendra (enlicitide) 20 mg tablets, developed by Merck Sharp & Dohme LLC, as the first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for reducing low density lipoprotein cholesterol (LDL C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) (1,2).

Lipfendra is indicated as an adjunct to diet and exercise for adults requiring additional LDL C reduction despite existing lipid lowering therapy (1,2). Formulated as a macrocyclic peptide, this once daily oral therapy blocks PCSK9 binding to LDL receptors, delivering an oral alternative to injectable PCSK9 targeted therapy (1,2).

The FDA reviewed the application under Priority Review and the Commissioner’s National Priority Voucher (CNPV) pilot program, designed to accelerate evaluation of therapies addressing national public health priorities (1).

Lipfendra: Drug Profile and Clinical Evidence

Lipfendra (enlicitide) is a macrocyclic peptide that disrupts the interaction between PCSK9 and LDL receptors (2). Its FDA approval was supported by two Phase 3 randomized, double blind, placebo controlled trials conducted under the CORALreef program, which enrolled 3,207 adults on maximally tolerated statin therapy (1,2).

CORALreef Lipids trial

In the CORALreef Lipids trial (NCT05952856), 2,904 adults with ASCVD or high ASCVD risk and a mean baseline LDL C of 96 mg/dL were studied. Lipfendra 20 mg once daily achieved a 56% placebo adjusted reduction in LDL C at Week 24 (95% CI: −61, −51; p<0.001) (1,2). A post hoc analysis excluding patients with baseline LDL C values ≤0 showed a 60% reduction (2). Secondary endpoints at Week 24 demonstrated mean reductions of 54% in non HDL C and 50% in apolipoprotein B (ApoB) (2,3).

CORALreef HeFH trial

In the CORALreef HeFH trial (NCT05952869), which enrolled 303 patients with heterozygous familial hypercholesterolemia (HeFH) and a mean baseline LDL C of 119 mg/dL, Lipfendra achieved a 59% placebo adjusted reduction in LDL C at Week 24 (95% CI: −66, −53; p<0.001), accompanied by mean reductions of 52% in non HDL C and 48% in ApoB (1,2, 4). These findings highlight Lipfendra’s robust LDL C lowering efficacy across both high risk ASCVD populations and patients with HeFH.

Clinical Benefits & Indications

Lipfendra is FDA approved as an adjunct to diet and exercise for reducing LDL C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) (1,2). Across two Phase 3 trials, Lipfendra demonstrated placebo adjusted LDL C reductions of 56% to 59%, with a once daily oral tablet (1,2). As the first oral PCSK9 inhibitor, Lipfendra expands therapeutic options for patients requiring additional LDL C lowering beyond existing therapies (1,2).

Dr. Ann Marie Navar, lead author of the CORALreef Lipids trial, emphasized that Lipfendra provides an oral alternative for LDL C reduction, while Dr. Dean Y. Li, President of Merck Research Laboratories, highlighted that macrocyclic peptide technology enables patients to achieve potent LDL C lowering with an oral treatment option (2).

Safety, Precautions, and Monitoring

Across the Phase 3 trials, the safety profile of Lipfendra was generally comparable to placebo (1,2). In the CORALreef Lipids trial, the overall frequency of adverse reactions was similar between the Lipfendra and placebo groups (1,2). In the CORALreef HeFH trial, adverse events reported more frequently with Lipfendra than placebo included diarrhea (7% vs. 2%) and dizziness (9% vs. 4%). Importantly, discontinuation rates due to adverse reactions were low and consistent across both treatment arms in the two trials (1,2). Clinicians are advised to assess lipid levels prior to initiation and to monitor response periodically during therapy (1,2).

Clinical Perspective

The FDA approval of Lipfendra marks the introduction of the first once daily oral PCSK9 inhibitor into clinical practice, expanding treatment options alongside statins, ezetimibe, and injectable therapies (1). In the Phase 3 CORALreef trials, Lipfendra achieved placebo adjusted LDL C reductions of 56% to 59%, offering an oral alternative for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), who require additional LDL C lowering (1,2). While LDL C reduction with statins and monoclonal antibody PCSK9 inhibitors has been associated with reduced cardiovascular event risk, the impact of Lipfendra on cardiovascular morbidity and mortality is being evaluated in the ongoing CORALreef Outcomes trial (NCT06008756), which is enrolling more than 14,500 participants. Beyond this, the broader CORAL program is assessing enlicitide in over 19,000 participants across extension, pediatric, and combination studies to further define its clinical utility and long term role in lipid management (2).

About the Author

Dr. Manisha Dadlani is a Dental Surgeon and Medical Writer with 5+ years of clinical experience and formal training in medical writing. She combines clinical expertise with analytical thinking to develop evidence-based, insight-driven content that supports effective scientific communication across the healthcare and life sciences landscape.

References:

U.S. Food and Drug Administration (FDA). FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol Accessed on 21 September, 2026.
Merck & Co., Inc. Merck’s LIPFENDRA® (enlicitide) is the first and only once-daily oral PCSK9 inhibitor approved by the U.S. FDA to reduce LDL-C in adults with hypercholesterolemia. Available at: https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/ Accessed on 21 September, 2026.
Navar AM, Mikhailova E, Catapano AL, et al. A Placebo‑Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. New England Journal of Medicine. 2026;394(6):529‑539.
Ballantyne CM, Gellis L, Tardif JC, et al. Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial. JAMA. 2026;335(2):129 39.

Disclaimer

The content published on this platform has been developed by independent medical writers from diverse healthcare backgrounds, including members of the MedWriters Alumni Network. While every effort has been made to ensure accuracy, the authors, Rxnews team, partners, agents, and sponsors accept no responsibility for errors, omissions, or inaccuracies in this article, whether due to negligence or otherwise, nor for any consequences arising from its use. Inclusion or exclusion of any product does not imply endorsement or rejection by the publisher. For complaints or feedback, please write to contact@rxnews.in